Licensing and Other Arrangements - Janssen Biotech (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 12 Months Ended | |
|---|---|---|---|---|
Aug. 31, 2019 |
Mar. 31, 2020 |
Mar. 31, 2019 |
Dec. 31, 2019 |
|
| Licensing and other arrangements | ||||
| Revenue from contracts with customers | $ 500 | $ 8,026 | ||
| Janssen Biotech Inc. | License Agreement | ||||
| Licensing and other arrangements | ||||
| One-time payment | $ 2,500 | |||
| Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events | $ 3,000 | |||
| Percentage of royalty on worldwide net sales of each product upon commercialization | 0.75% | |||
| Revenue from contracts with customers | 0 | $ 2,500 | ||
| Contract assets | 0 | |||
| Contract liabilities | 0 | |||
| Capitalized contract costs | $ 0 | |||
| X | ||||||||||
- Definition Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events. No definition available.
|
| X | ||||||||||
- Definition One-time payment. No definition available.
|
| X | ||||||||||
- Definition Percentage of royalty on net sales upon commercialization. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|